Deals
Abbott Labs' Good Timing
Patience paid off in its bidding for Alere.
This article is for subscribers only.
Abbott Labs, having waited and waited for the right time to re-enter the deal sphere, finally saw an opportunity and pounced.
The $56 billion company said Monday it's buying Alere, a diagnostics business, in what will be its first major acquisition since spinning off AbbVie three years ago.